Prescient Therapeutics was delighted to attend the recent San...

Prescient Therapeutics was delighted to attend the recent San Antonio Breast Cancer Symposium (SABCS), the premier conference focussed exclusively on breast cancer.
It is not often appreciated by those outside the sector just how broad and diverse the field of breast cancer treatment is – not just by tumour subtypes, but stage of disease.
Overall, there continues to be incremental progress in the field from a variety of angles, and there remains plenty of need for new therapeutic interventions.

Of particular relevance to Prescient, the PI3K/Akt pathway was discussed at length and of substantial interest. The important role of PH domains was discussed, but interestingly not as targets – this confirms that PTX-200 remains well differentiated as a PH domain inhibitor with utility in Akt inhibition.

PTX-200’s early response rates in breast cancer, together with our recently announced interim durability data, combine favourably when compared with other therapies presented at SABCS at similar stages of development. If the development trend continues, PTX-200 will attract increasing interest.
Amongst our meetings, were pleased to catch up with our investigators, Professor Joseph Sparano and Dr Heather Han, who are pleased with the progress of our breast cancer trial.
Literally thousands of people packed out a plenary session to hear Professor Sparano deliver his thoughts on treatments for localised and locally advanced breast cancer. As the world gets better at screening and diagnosis, the focus on this earlier stage of disease becomes increasingly important.

It is an honour for Prescient to have someone of Professor Sparano’s international standing lead our breast cancer trial. (Pictured here between Prescient CMO Dr Terry Chew (left) and CEO Steven Yatomi-Clarke (right)).